Antigen-specific autoreactive CD4+ T lymphocyte (Autoreactive CD4+ T cell)

Antigen-specific autoreactive CD4+ T lymphocytes are a subset of T cells that recognize self-antigens presented by Major Histocompatibility Complex class II (MHC-II) molecules, serving as primary drivers of autoimmune pathology (Source: Nature Reviews Immunology, 2020). In diseases such as Type 1 Diabetes and Multiple Sclerosis, these cells escape thymic selection and initiate inflammatory cascades against host tissues. Tolerogenic dendritic cells (tolDCs) are engineered or pharmacologically modulated to present these same disease-associated peptides but lack the costimulatory signals (e.g., CD80, CD86) required for T-cell activation (Source: Frontiers in Immunology, 2021). Instead, the interaction between the tolDC MHC-II-peptide complex and the autoreactive T-cell receptor (TCR) leads to peripheral tolerance. This is achieved through the induction of T-cell anergy, apoptosis, or the conversion of pathogenic cells into FoxP3+ regulatory T cells (Tregs) (Source: JCI Insight, 2019). This therapeutic approach aims to provide a precise, antigen-specific treatment that avoids the side effects of systemic immunosuppressants. By targeting the specific TCR-MHC-II interaction, researchers hope to reprogram the immune system to ignore specific self-tissues while maintaining normal defense against pathogens.

Other names

Autoreactive T cellsPathogenic CD4+ T cellsSelf-reactive T lymphocytesMHC-II restricted autoreactive T cells

Induction of antigen-specific peripheral tolerance via T-cell anergy, deletion, or regulatory T-cell (Treg) differentiation.